Changing landscape of psoriasis therapy

Since the mid-1980s, mounting evidence has shown that psoriasis is an immune disorder - specifically, that abnormal T-cell activity is a critical component of the disease.

Related Videos
Related Content

Oral Vitamin D Supplementation May Lower Melanoma Risk

March 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Oleogel-S10 for Epidermolysis Bullosa Wounds Demonstrated Accelerated Healing

March 22nd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Risankizumab Efficacious in Patients with Prior Plaque Psoriasis Biologic Use

March 22nd 2023

New TMB-001 Sub-Analysis Data Published in Clinical and Experimental Dermatology

March 22nd 2023

Oral Vitamin D Supplementation May Lower Melanoma Risk

March 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Oleogel-S10 for Epidermolysis Bullosa Wounds Demonstrated Accelerated Healing

March 22nd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Risankizumab Efficacious in Patients with Prior Plaque Psoriasis Biologic Use

March 22nd 2023

New TMB-001 Sub-Analysis Data Published in Clinical and Experimental Dermatology

March 22nd 2023

Oral Vitamin D Supplementation May Lower Melanoma Risk

March 22nd 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Oleogel-S10 for Epidermolysis Bullosa Wounds Demonstrated Accelerated Healing

March 22nd 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

Risankizumab Efficacious in Patients with Prior Plaque Psoriasis Biologic Use

March 22nd 2023

New TMB-001 Sub-Analysis Data Published in Clinical and Experimental Dermatology

March 22nd 2023
© 2023 MJH Life Sciences

All rights reserved.